Gut–brain axis

Purpose of reviewTo summarize recent studies on the regulation and the functions of the gut–brain axis. Recent findingsVisual cues of food and food intake interact with the gut–brain axis at the level of the hypothalamus. However, the hypothalamic response to glucose intake is considerably altered in patients with type 2 diabetes mellitus, indicating involvement of the hypothalamus in the pathophysiology of this disease in humans. A large number of studies have documented the functions of gut peptides with respect to the regulation of satiety. Gut peptides are involved in the regulation of insulin secretion and sensitivity. Recent data indicate that peptide YY is a gut hormone that also modulates bone metabolism. Increasing evidence is obtained on the role of afferent gastrointestinal nerves, especially the vagal nerve, in the modulation of the functions of the gut–brain axis. SummaryThe gut–brain axis is involved in a multitude of physiological processes including satiety, food intake, regulation of glucose and fat metabolism, insulin secretion and sensitivity and bone metabolism. It is likely, that more aspects of this system will be found the near future.

[1]  P. Baldock,et al.  PYY transgenic mice are protected against diet-induced and genetic obesity , 2008, Neuropeptides.

[2]  D. Ffytche,et al.  PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans , 2007, Nature.

[3]  J. Herman,et al.  Peptide YY regulates bone turnover in rodents. , 2007, Gastroenterology.

[4]  S. Bloom,et al.  Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.

[5]  Jason R Tregellas,et al.  Effects of overfeeding on the neuronal response to visual food cues. , 2007, The American journal of clinical nutrition.

[6]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[7]  Jeroen van der Grond,et al.  Glucose Ingestion Fails to Inhibit Hypothalamic Neuronal Activity in Patients With Type 2 Diabetes , 2007, Diabetes.

[8]  Y. Li.  Sensory signal transduction in the vagal primary afferent neurons. , 2007, Current medicinal chemistry.

[9]  E. Ravussin,et al.  Peptide YY: obesity's cause and cure? , 2007, American journal of physiology. Endocrinology and metabolism.

[10]  A. Astrup,et al.  Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. , 2007, American journal of physiology. Endocrinology and metabolism.

[11]  Astrid A. Ortiz,et al.  Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. , 2007, Journal of medicinal chemistry.

[12]  Birgitte Sloth,et al.  Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. , 2007, American journal of physiology. Endocrinology and metabolism.

[13]  C. Koebnick,et al.  Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. , 2007, The Journal of clinical endocrinology and metabolism.

[14]  D. Cummings,et al.  Gastrointestinal regulation of food intake. , 2007, The Journal of clinical investigation.

[15]  J. H. Peters,et al.  Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin , 2006, Physiology & Behavior.

[16]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[17]  Jimmy D Bell,et al.  Critical role for peptide YY in protein-mediated satiation and body-weight regulation. , 2006, Cell metabolism.

[18]  G. Królczyk,et al.  Influence of vagal nerve stimulation on food intake and body weight--results of experimental studies. , 2005, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[19]  Stephen R. Bloom,et al.  The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.

[20]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[21]  Stephen R. Bloom,et al.  Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake , 2005, Brain Research.

[22]  X. Y. Wu,et al.  Serotonin and cholecystokinin synergistically stimulate rat vagal primary afferent neurones , 2004, The Journal of physiology.

[23]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[24]  G. Thomas,et al.  Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.

[25]  H. Pijl,et al.  Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. , 2007, American journal of physiology. Endocrinology and metabolism.

[26]  H. Pijl,et al.  Chronic PYY 3 – 36 treatment promotes fat oxidation and ameliorates insulin resistance in C 57 BL 6 mice , 2006 .

[27]  David Grundy,et al.  Extrinsic Sensory Afferent Nerves Innervating the Gastrointestinal Tract , 2006 .

[28]  Terry L. Powley,et al.  The fiber composition of the abdominal vagus of the rat , 2004, Anatomy and Embryology.